Bioconjugate structures vs. composite nanoparticuIate carriers: the battIe for the future of smart, effective and safe cancer management

摘要

For the past couple of decades, academic research has been mainly focusing on novel carrier systems and nanoparticulate colloidal technologies for drug delivery, such as nanoparticles, nanospheres, vesicular systems, liposomes, nanocapsules, etc. Such efforts aided in the creation of newly marketed products such as Doxil? in the market[1,2].